Predictors of response and long-term tolerability of sparsentan in a real-world IgA nephropathy cohort

Clicks: 68
ID: 327149
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #9 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Sparsentan, a dual endothelin type A and angiotensin II type 1 receptor antagonist (DEARA), has demonstrated antiproteinuric efficacy in randomized trials of IgA nephropathy (IgAN). However, real-world data on treatment response and predictors remain limited. We evaluated longitudinal proteinuria response, kidney function trajectories, and predictors of treatment response over the first year of sparsentan therapy in routine practice. Methods In this single-center observational study, 38 adults with biopsy-proven IgAN were evaluated at baseline, 3, 6, 9, and 12 months after sparsentan initiation. Predictors of response, defined as ≥ 50% proteinuria reduction with ≤ 15% decline in estimated glomerular filtration rate (eGFR), were evaluated at the 9-month landmark analysis using logistic regression. Longitudinal proteinuria and eGFR trajectories were analyzed using linear mixed models. Results Sparsentan was associated with sustained proteinuria reduction across patient subgroups. In mixed-effects models, proteinuria declined by approximately 8% per month, while the annualized eGFR slope was − 2.5 mL/min/1.73 m²/year. At the 9-month landmark analysis, baseline hematuria (OR 10.00; 95% CI 1.28–78.12; P = 0.028) and higher systolic blood pressure (sBP) (OR 4.30; 95% CI 1.02–18.10; P = 0.047) were associated with higher odds of response. Sparsentan was generally well tolerated, with discontinuation in 10.5% of patients, including two cases of reversible liver enzyme elevation. Conclusion In routine practice, sparsentan was associated with sustained antiproteinuric effects with relatively stable kidney function trajectories despite advanced baseline disease. Exploratory analysis identified baseline hematuria and sBP as potential markers of treatment response; however, these findings require validation in larger prospective cohorts.
Reference Key
openalex_W7204801730 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anila Cara, Maria J Vargas-Brochero, Cristián Juanet, Gian Marco Berti, Ilario Russo, Fernando C. Fervenza, Ladan Zand
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag291
URL
https://academic.oup.com/ckj/advance-article-pdf/doi/10.1093/ckj/sfag291/70881956/sfag291.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.